Archive for month: July, 2025

What if a blood test could reveal the pace of our aging – and the diseases that may lie ahead? The labs of Profs. Liran Shlush and Amos Tanay at the Weizmann Institute of Science have been conducting in-depth studies into the biology of blood to better understand the aging process and why some people become more susceptible to disease over the years. Their research teams, made up of physicians, biologists and data scientists, have been tracking changes in the blood-forming stem cells, including the emergence of genetic changes in these cells in about one-third of people over the age of 40. These changes not only increase the risk of blood cancers such as leukemia, but have also been linked to heart disease, diabetes and other age-related conditions.

In a new study published today (Friday) in Nature Medicine – just days after their labs were severely damaged in an Iranian missile attack – Shlush and Tanay present findings that may lead to an innovative blood test for detecting a person’s risk of developing leukemia. This test may potentially replace the invasive diagnostic procedure of bone marrow sampling.

The study focused on myelodysplastic syndrome (MDS), an age-related condition in which blood stem cells fail to properly mature into functional blood cells. Diagnosing MDS and assessing its severity is crucial, as it can lead to severe anemia and may progress to acute myeloid leukemia, one of the most common blood cancers in adults. Until now, diagnosis has relied on bone marrow sampling, a procedure that requires local anesthesia and can cause discomfort or pain.

In the new study, a research team led by Dr. Nili Furer, Nimrod Rappoport and Oren Milman, in collaboration with physicians and researchers in Israel and the United States, showed that rare blood stem cells – which occasionally exit the bone marrow and enter the bloodstream – carry diagnostic information about MDS. The researchers demonstrated that with a simple blood test and advanced single-cell genetic sequencing, it is possible to identify early signs of the syndrome and even assess a person’s risk of developing blood cancer.

The researchers also discovered that the migrating stem cells can serve as a clock for our chronological age, and that in males, their population changes earlier than in women in a way that increases the risk of cancer. This finding may explain the higher prevalence of blood cancers among men. The scientists believe that using the test to diagnose MDS and leukemia is only the beginning, and that in the future it could be applied to a range of other blood-related disorders. The current findings are already being tested in a large-scale clinical trial at several medical centers around the world.

In addition to his laboratory research, Shlush is also a senior physician at Assuta Medical Center in Ashdod and at Maccabi Healthcare Services, and he heads the newly established Miriam and Aaron Gutwirth Medical School at the Weizmann Institute. The school was founded to address the emerging needs and challenges of the worlds of medicine and research and to bridge, as much as possible, the gap between today’s science and tomorrow’s medicine. Unlike existing programs around the world that combine medicine with research, the new program is expected to unify and intertwine the clinical and research components. The school is scheduled to open its doors for the first time this coming October and aims to train the next generation of physician-scientists.

Reference:

Furer, N., Rappoport, N., Milman, O. et al. A reference model of circulating hematopoietic stem cells across the lifespan with applications to diagnostics. Nat Med (2025). https://doi.org/10.1038/s41591-025-03716-5.

Kerala- The Commissioner for Entrance Examinations (CEE) Kerala is inviting allotment to Postgraduate (PG) Dental Master of Dental Surgery (MDS) Courses, Kerala for the academic year 2025. In this regard, CEE Kerala has issued a notification detailing the schedule, list of Colleges included in the Allotment, fees and other important details.

Bangalore: AstraZeneca Pharma India Limited has received permission from the Central
Drugs Standard Control Organisation (CDSCO), Directorate General of Health Services, Government of India to
import for sale and distribution of Durvalumab Solution for Infusion 120 mg/2.4 ml and 500 mg/10 ml
(Brand name: Imfinzi) for an additional indication.

Through this approval, Durvalumab in combination with carboplatin and paclitaxel is indicated for the
first-line treatment of adults with primary advanced or recurrent endometrial cancer who are candidates
for systemic therapy, followed by maintenance treatment with Durvalumab in combination with
olaparib in endometrial cancer that is mismatch repair proficient (pMMR).

The receipt of this permission paves way for the marketing of Durvalumab Solution for Infusion 120
mg/2.4 ml and 500 mg/10 ml (Brand name: Imfinzi) in India for the specified additional indication,
subject to the receipt of related statutory approvals, if any.

Read also: AstraZeneca-Daiichi Sankyo Datroway gets USFDA accelerated nod for previously treated advanced EGFR-mutated non-small cell lung cancer

In March this year, AstraZeneca Pharma India received CDSCO approval to import for sale and distribution of Imfinzi for patients with limited-stage small cell lung cancer (LS-SCLC) whose disease has not progressed following platinum-based chemoradiation therapy.

Additionally, earlier in the same month, the company obtained permission for Durvalumab in combination with Tremelimumab for patients with unresectable hepatocellular carcinoma (uHCC). Hepatocellular carcinoma (HCC) is a type of liver cancer. Because symptoms often don’t appear until the advanced stages, getting diagnosed with liver cancer like HCC can come as a shock. 

Read also: AstraZeneca Pharma India secures CDSCO nod to import, sell Durvalumab for small cell lung cancer

Read also: AstraZeneca Pharma India names Praveen Rao Akkinepally as new MD, succeeding Dr Sanjeev Panchal